Abstract:Apolipoprotein (apo) E4 is the major genetic risk factor for Alzheimer's disease (AD), increasing risk and decreasing age of disease onset. Many studies have demonstrated the detrimental effects of apoE4 in varying cellular contexts. However, the underlying mechanisms explaining how apoE4 leads to cognitive decline are not fully understood. Recently, the combination of human induced pluripotent stem cell (hiPSC) modeling of neurological diseases in vitro and electrophysiological studies in vivo have begun to unravel the intersection between apoE4, neuronal subtype dysfunction or loss, subsequent network deficits, and eventual cognitive decline. In this review, we provide an overview of the literature describing apoE4's detrimental effects in the central nervous system (CNS), specifically focusing on its contribution to neuronal subtype dysfunction or loss. We focus on γ-aminobutyric acid (GABA)-expressing interneurons in the hippocampus, which are selectively vulnerable to apoE4-mediated neurotoxicity. Additionally, we discuss the importance of the GABAergic inhibitory network to proper cognitive function and how dysfunction of this network manifests in AD. Finally, we examine how apoE4-mediated GABAergic interneuron loss can lead to inhibitory network deficits and how this deficit results in cognitive decline. We propose the following working model: Aging and/or stress induces neuronal expression of apoE. GABAergic interneurons are selectively vulnerable to intracellularly produced apoE4, through a tau dependent mechanism, which leads to their dysfunction and eventual death. In turn, GABAergic interneuron loss causes hyperexcitability and dysregulation of neural networks in the hippocampus and cortex. This dysfunction results in learning, memory, and other cognitive deficits that are the central features of AD.

Neuronal ApoE4 in Alzheimer's disease and potential therapeutic targets

Roles of ApoE4 on the Pathogenesis in Alzheimer's Disease and the Potential Therapeutic Approaches

Neuronal ApoE4 stimulates C/EBPβ activation, promoting Alzheimer’s disease pathology in a mouse model

Apolipoprotein E in Alzheimer's Disease: Focus on Synaptic Function and Therapeutic Strategy

Apolipoprotein E4, inhibitory network dysfunction, and Alzheimer’s disease

Apolipoprotein E in Alzheimer’s Disease: Focus on Synaptic Function and Therapeutic Strategy

Aβ Metabolism and the Role of APOE in Alzheimer’s Disease

Neuronal APOE4 removal protects against tau-mediated gliosis, neurodegeneration and myelin deficits

ApoE4: an emerging therapeutic target for Alzheimer’s disease

Role of Apolipoprotein E in Alzheimer's Disease Pathogenesis, Prognosis and Treatment

Detrimental Effects of ApoE ε4 on Blood-Brain Barrier Integrity and Their Potential Implications on the Pathogenesis of Alzheimer's Disease

Cell type-specific roles of APOE4 in Alzheimer disease

The Contributions of the Endolysosomal Compartment and Autophagy to APOE ɛ4 Allele-Mediated Increase in Alzheimer's Disease Risk

APOE and Alzheimer’s Disease: From Lipid Transport to Physiopathology and Therapeutics

The Contributions of the Endolysosomal Compartment and Autophagy to APOEɛ4 Allele-Mediated Increase in Alzheimer's Disease Risk

ApoE4-mediated Blood-Brain Barrier Damage in Alzheimer's Disease: Progress and Prospects

Multiple Effect of APOE Genotype on Clinical and Neuroimaging Biomarkers Across Alzheimer’s Disease Spectrum

ApoE4 Impairs Neuron-Astrocyte Coupling of Fatty Acid Metabolism

Neuronal apolipoprotein E4 increases cell death and phosphorylated tau release in alzheimer disease

AÃÂ² Metabolism and the Role of APOE in AlzheimerÃ¢ÂÂs Disease

ApoE Lipidation as a Therapeutic Target in Alzheimer’s Disease